PDS Biotechnology Corp Market Cap ($73.92 Million)
Market Cap & Net Worth: PDS Biotechnology Corp (PDSB)
PDS Biotechnology Corp market cap. PDS Biotechnology Corp (NASDAQ:PDSB) has a market capitalization of $73.92 Million ($73.92 Million) as of November 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20221 globally and #4619 in its home market, demonstrating a 23.42% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PDS Biotechnology Corp's stock price $1.37 by its total outstanding shares 72474208 (72.47 Million). Also see PDSB cash flow conversion for how efficiently the company converts equity into cash flow.
PDS Biotechnology Corp Market Cap History (2015–2026)
PDS Biotechnology Corp market cap history from 2015 to 2026. Data shows change from $18.12 Billion to $99.29 Million (-40.80% CAGR). Check latest PDS Biotechnology Corp stock price today for real-time trading data and today's change.
Index Memberships
PDS Biotechnology Corp is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.00% | #564 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #1937 of 3165 |
Weight: PDS Biotechnology Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
PDS Biotechnology Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PDS Biotechnology Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of PDS Biotechnology Corp to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PDSB by Market Capitalization
Companies near PDS Biotechnology Corp in the global market cap rankings as of November 3, 2026. Also see PDS Biotechnology Corp balance sheet assets for a full breakdown of the balance sheet.
Key companies related to PDS Biotechnology Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of PDS Biotechnology Corp (2015–2026)
Market capitalization of PDS Biotechnology Corp from 2015 to today. Between 2015 and today, PDS Biotechnology Corp's market cap moved from $18.12 Billion to $ 99.29 Million, with a yearly change of -40.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $99.29 Million | +77.97% |
| 2025 | $55.79 Million | -52.77% |
| 2024 | $118.13 Million | -67.20% |
| 2023 | $360.20 Million | -62.35% |
| 2022 | $956.66 Million | +62.96% |
| 2021 | $587.04 Million | +278.50% |
| 2020 | $155.09 Million | -19.25% |
| 2019 | $192.06 Million | -58.72% |
| 2018 | $465.28 Million | -96.57% |
| 2017 | $13.58 Billion | -25.04% |
| 2016 | $18.12 Billion | 0.00% |
| 2015 | $18.12 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of PDS Biotechnology Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $73.92 Million USD |
| MoneyControl | $73.92 Million USD |
| MarketWatch | $73.92 Million USD |
| marketcap.company | $73.92 Million USD |
| Reuters | $73.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PDS Biotechnology Corp
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are… Read more